Lung cancer patients who received IV immunotherapy doses earlier in the day tended to live longer, researchers reported in a ...

Patients with extensive-stage SCLC who received immunochemotherapy before 15:00 hrs exhibited significantly longer PFS, overall survival.

Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, as well as emerging cell, radiotherapy and combination approaches, during an ...

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

BioNTech SE (NASDAQ:BNTX) traded 3.1% higher in Monday’s premarket session after the company, alongside partner OncoC4, ...

Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Small cell lung cancer (SCLC) may increase the risk of pneumonia due to a weakened immune system or structural changes to the lungs. SCLC is one of the two main types of lung cancer. Pneumonia is an ...

Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed ...

In this study, researchers sought to determine whether Medicaid expansion led to improvements in survival for patients with resectable NSCLC.

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

Early-stage non-small cell lung cancer (NSCLC) offers a better prognosis than advanced stages. Staging helps inform treatment by describing your cancer's size, lymph node involvement, and metastasis.